Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) CEO Timothy P. Walbert sold 25,000 shares of the business’s stock in a transaction dated Friday, May 20th. The stock was sold at an average price of $90.00, for a total value of $2,250,000.00. Following the transaction, the chief executive officer now owns 460,549 shares in the company, valued at approximately $41,449,410. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Horizon Therapeutics Public stock traded up $1.01 during midday trading on Friday, hitting $90.35. The stock had a trading volume of 1,848,750 shares, compared to its average volume of 1,839,478. The company has a current ratio of 3.57, a quick ratio of 3.30 and a debt-to-equity ratio of 0.53. The business has a fifty day moving average price of $103.50 and a 200 day moving average price of $101.28. Horizon Therapeutics Public Limited has a 12 month low of $82.51 and a 12 month high of $120.54. The stock has a market cap of $20.77 billion, a P/E ratio of 24.48, a P/E/G ratio of 1.24 and a beta of 1.11.
Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last issued its earnings results on Wednesday, May 4th. The biopharmaceutical company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.20. Horizon Therapeutics Public had a return on equity of 32.08% and a net margin of 22.87%. The company had revenue of $885.25 million during the quarter, compared to the consensus estimate of $866.39 million. During the same period in the previous year, the firm posted $0.03 earnings per share. Horizon Therapeutics Public’s quarterly revenue was up 158.5% compared to the same quarter last year. On average, equities analysts anticipate that Horizon Therapeutics Public Limited will post 5.59 EPS for the current fiscal year.
HZNP has been the topic of a number of recent research reports. StockNews.com initiated coverage on Horizon Therapeutics Public in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Zacks Investment Research upgraded Horizon Therapeutics Public from a “strong sell” rating to a “hold” rating and set a $104.00 price objective on the stock in a research note on Thursday, March 3rd. Piper Sandler dropped their target price on Horizon Therapeutics Public from $143.00 to $133.00 in a research report on Wednesday, January 26th. Morgan Stanley lifted their target price on Horizon Therapeutics Public from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 2nd. Finally, Wells Fargo & Company reaffirmed a “buy” rating and set a $133.00 target price on shares of Horizon Therapeutics Public in a research report on Friday, April 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $133.67.
About Horizon Therapeutics Public (Get Rating)
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.
- Get a free copy of the StockNews.com research report on Horizon Therapeutics Public (HZNP)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.